Your browser is no longer supported. Please, upgrade your browser.
Settings
MBRX Moleculin Biotech, Inc. daily Stock Chart
MBRX [NASD]
Moleculin Biotech, Inc.
Index- P/E- EPS (ttm)-0.46 Insider Own23.73% Shs Outstand46.38M Perf Week-8.13%
Market Cap52.41M Forward P/E- EPS next Y-0.45 Insider Trans0.00% Shs Float27.47M Perf Month1.80%
Income-11.90M PEG- EPS next Q-0.11 Inst Own6.60% Short Float12.43% Perf Quarter-13.73%
Sales- P/S- EPS this Y13.20% Inst Trans29.76% Short Ratio0.89 Perf Half Y-11.02%
Book/sh0.51 P/B2.22 EPS next Y-16.70% ROA-65.20% Target Price5.50 Perf Year-34.68%
Cash/sh0.19 P/C5.96 EPS next 5Y- ROE-92.20% 52W Range0.78 - 3.15 Perf YTD8.65%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-63.81% Beta-
Dividend %- Quick Ratio1.50 Sales past 5Y- Gross Margin- 52W Low46.68% ATR0.20
Employees9 Current Ratio1.50 Sales Q/Q- Oper. Margin- RSI (14)44.41 Volatility5.39% 17.01%
OptionableNo Debt/Eq0.00 EPS Q/Q-68.30% Profit Margin- Rel Volume0.11 Prev Close1.13
ShortableYes LT Debt/Eq0.00 EarningsMay 21 BMO Payout- Avg Volume3.82M Price1.14
Recom2.00 SMA20-14.51% SMA50-5.98% SMA200-16.14% Volume63,069 Change0.88%
Dec-20-17Initiated ROTH Capital Buy $8
May-14-19 07:30AM  Moleculin Biotech, Inc. Reports Financial Results for the First Quarter Ended March 31, 2019 PR Newswire
May-07-19 07:30AM  Moleculin Announces Additional Positive Interim Results in First Cohort of Phase 1/2 Clinical Studies of Annamycin in Acute Myeloid Leukemia in Europe PR Newswire +6.06%
Apr-29-19 09:00AM  Generex Biotechnology Announces Organizational Roadmap & Investor Conference Call: Update on Product Launch, New Acquisitions, Financing, Expansion Initiatives & Strategic Plans PR Newswire
08:00AM  Positive Results From HMN Lithium Project P.E.A. PR Newswire
08:00AM  Positive Results From HMN Lithium Project P.E.A. CNW Group
07:00AM  US Biopharma Company Undertakes Anti-Cancer Clinical Trials in Poland, First Patient Showing Positive Initial Treatment PR Newswire
Apr-23-19 08:40AM  Moleculin Announces $15.0 Million Registered Direct Offering PR Newswire -46.64%
08:08AM  The Daily Biotech Pulse: FDA Accepts Alder's Migraine Drug Application, Gritstone Offering, Lilly's Chinese Sale Benzinga
Apr-22-19 07:30AM  Moleculin Announces Conference Call to Discuss Significant Discovery For Lung Cancer and FDA Activity on Wednesday, April 24, 2019 PR Newswire +168.47%
Apr-18-19 07:30AM  Moleculin Receives FDA Approval of Fast Track Designation for Annamycin PR Newswire +14.08%
Apr-17-19 07:30AM  Moleculin Announces Significant Discovery in Lung Cancer Models PR Newswire +6.61%
Apr-11-19 07:30AM  Moleculin Announces Agreement with Emory University to Conduct Pediatric Brain Tumor Trial PR Newswire
Apr-09-19 07:30AM  Moleculin Announces Successful Expansion of its Leukemia Drug Program PR Newswire
Apr-03-19 07:30AM  Moleculin Announces Preclinical Pancreatic Cancer Data Presented at American Association for Cancer Research Annual Meeting PR Newswire
Apr-01-19 03:10AM  EnerCube Completes Complex Design Project With Altasteel PR Newswire +10.28%
Mar-27-19 09:05AM  Moleculin Announces Pricing Of Underwritten Public Offering PR Newswire -30.83%
Mar-26-19 05:37PM  Moleculin Announces Proposed Underwritten Public Offering PR Newswire -6.26%
07:30AM  Moleculin Announces Positive Interim Results in First Cohort of Phase 1/2 Clinical Studies of Annamycin in Acute Myeloid Leukemia in the US and in Poland PR Newswire
Mar-19-19 07:30AM  Moleculin Announces First Patients Enrolled in Lymphoma Clinical Trial PR Newswire
Mar-18-19 04:05PM  Moleculin Announces Memorial Sloan Kettering Chief of Leukemia Joins Science Advisory Board PR Newswire
07:30AM  Moleculin Biotech, Inc. to Present at the Oppenheimer 29th Annual Healthcare Conference and the 31st Annual ROTH Conference PR Newswire
Mar-14-19 07:30AM  Moleculin Announces First Patients Treated in European Annamycin Clinical Trial ACCESSWIRE
Mar-13-19 07:30AM  Moleculin Files with FDA for Expedited Approval Pathway for Annamycin ACCESSWIRE
Feb-22-19 08:50AM  The Daily Biotech Pulse: BioMarin Slips On Earnings, TherapeuticsMD Posts In-Line Results, Orchard To Present Immunodeficiency Drug Data Benzinga
Feb-21-19 04:59PM  Moleculin Biotech, Inc. Reports Financial Results for the Year Ended December 31, 2018 GlobeNewswire
Feb-20-19 07:30AM  Moleculin Announces Outlicensing Deal To Accelerate Preclinical and Clinical Development GlobeNewswire
Feb-19-19 03:05AM  Northern Lights Supply Store in Alberta Receives First Inventory in Preparation for Grand Opening PR Newswire -10.89%
Feb-14-19 07:30AM  Premier Health Provides Corporate Update PR Newswire
Feb-07-19 07:30AM  Moleculin Announces Approval for Third Drug to Commence Clinical Trials GlobeNewswire
Feb-05-19 09:20AM  4 Healthcare Stocks The Market is Watching on Tuesday (2/5/19) ACCESSWIRE +7.43%
07:30AM  Moleculin Announces the FDA has Granted Orphan Drug Designation for its Brain Tumor Drug GlobeNewswire
Jan-17-19 07:30AM  Moleculin Announces Dr. James L. Abbruzzese, Chief of Medical Oncology Division at Duke University, Joins Science Advisory Board GlobeNewswire
Jan-09-19 07:30AM  Moleculin Announces Patient Recruitment Begins in Annamycin Clinical Trial In Poland GlobeNewswire
Jan-07-19 10:06AM  Amarin Down on Lower '19 View, Posts Preliminary '18 Results Zacks +5.69%
Jan-03-19 07:30AM  Moleculin Announces Positive Data for its Pancreatic Cancer Drug Candidate GlobeNewswire
Dec-31-18 07:30AM  Report: Exploring Fundamental Drivers Behind Cronos Group, Henry Schein, Argo Group International, Eiger BioPharmaceuticals, China Automotive, and Moleculin Biotech New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Dec-12-18 06:55AM  Today's Research Reports on Trending Tickers: NeuroMetrix and Moleculin ACCESSWIRE
Dec-11-18 07:30AM  REMINDER: Moleculin Announces Conference Call to Discuss Recent Breakthrough Discovery and FDA Filing on Wednesday, December 12, 2018 GlobeNewswire +18.70%
Dec-06-18 04:05PM  Moleculin Announces Conference Call to Discuss FDA Filing and New Immune Checkpoint Data on Wednesday, December 12, 2018 GlobeNewswire
07:30AM  Moleculin Announces FDA Filing for Orphan Drug Designation for Glioblastoma Drug GlobeNewswire
Dec-04-18 07:30AM  Moleculin Announces Breakthrough Discovery for its WP1066 GlobeNewswire
Nov-28-18 07:30AM  Moleculin Announces New Data Further Supporting Its Lead Drug for Treating Pancreatic Cancer GlobeNewswire
Nov-19-18 08:45AM  Consolidated Research: 2018 Summary Expectations for Moleculin Biotech, Novan, PAVmed, Maui Land & Pineapple, Hallmark Financial Services, and McEwen Mining Fundamental Analysis, Key Performance Indications GlobeNewswire
Nov-15-18 07:30AM  Moleculin Requests FDA Meeting Regarding IND for New Cancer Drug GlobeNewswire +8.66%
Nov-13-18 07:30AM  Moleculin Biotech, Inc. Reports Financial Results for the Third Quarter Ended September 30, 2018 GlobeNewswire
Nov-08-18 07:30AM  Moleculin Announces New Independent Study Expands Potential Use of Its Pancreatic Drug Candidate WP1122 GlobeNewswire +9.60%
Nov-01-18 07:30AM  Moleculin Announces Significant Milestone Achieved in Glioblastoma Trial GlobeNewswire +9.62%
Oct-25-18 07:30AM  Moleculin Announces Positive Data on WP1066 in Pre-Clinical Trials GlobeNewswire +5.17%
Oct-10-18 07:30AM  Moleculin Announces New Data Discovery Confirming Significant Increase in Potential to Starve Cancerous Tumors GlobeNewswire
Sep-13-18 07:30AM  Moleculins Brain Cancer Drug Candidate Begins Patient Dosing at Clinical Trial Being Conducted at MD Anderson GlobeNewswire
Aug-13-18 07:30AM  Moleculin Biotech, Inc. Reports Financial Results for the Second Quarter Ended June 30, 2018 GlobeNewswire
Aug-09-18 07:30AM  Moleculin Seeks Approval from Polish Regulatory Agency for Skin Cancer Clinical Trial GlobeNewswire
Jul-31-18 07:30AM  Moleculin Announces Enrollment Opens for Brain Tumor Trial of WP1066 GlobeNewswire
Jul-18-18 07:30AM  Moleculin Expects to Meet FDA IND Filing Requirements for its Pancreatic Cancer Drug Candidate with Development Work in Australia GlobeNewswire
Jul-11-18 07:30AM  Moleculin Expands Operations to Australia; Taps R&D Incentive Program Capped at $20,000,000 AUD Turnover GlobeNewswire
Jun-26-18 07:30AM  Moleculin Selected for the Russell Microcap Index GlobeNewswire
Jun-21-18 07:30AM  Moleculin Announces $2.3 Million Registered Direct Offering Priced At-the-Market GlobeNewswire -13.82%
Jun-20-18 08:52AM  Benzinga Pro's 5 Stocks To Watch Today Benzinga +7.96%
07:30AM  Moleculin Receives Approval for Leukemia Clinical Trial GlobeNewswire
Jun-12-18 07:30AM  Moleculin Targets accelerated FDA approval of WP1732; Pursues Development for Ocular Tumors GlobeNewswire +6.45%
Jun-06-18 09:09AM  Moleculins Breakthrough Discovery of a New Molecule for Cancer Treatment Advances to Development Agreement with the University of Iowa GlobeNewswire
May-29-18 07:20AM  Nektar Therapeutics and Three Additional Biotech Stocks on Our Research Desks Radar ACCESSWIRE
May-24-18 08:30AM  Moleculin Invited to Present to International BioForum 2018 Conference GlobeNewswire
May-18-18 12:43PM  Who Owns Most Of Moleculin Biotech Inc (NASDAQ:MBRX)? Simply Wall St.
May-16-18 08:30AM  Moleculin to Begin Clinical Trials at UMC Southwest Cancer Center GlobeNewswire
May-15-18 08:30AM  Moleculin Biotech, Inc. Reports Financial Results for the First Quarter Ended March 31, 2018 GlobeNewswire
May-03-18 08:30AM  Moleculin Announces Engagement with Voisin Consulting Life Sciences to Expand Annamycin Clinical Trial GlobeNewswire
Apr-26-18 08:30AM  Moleculin Announces New Data for Immuno-Stimulating Drug to be Presented at International Conference Marketwired
Apr-12-18 07:00AM  Wired News Spectrum Pharma Reported Update Data from MD Andersons Phase-2 Data Assessing Poziotinib in EGFR Exon 20 Mutant NSCLC Patients ACCESSWIRE
Apr-04-18 08:30AM  Moleculin Announces Patients Treated in FDA Approved Phase I/II Annamycin Clinical Trial Marketwired
Mar-28-18 08:30AM  Moleculin Biotech, Inc. Reports Financial Results for the Year Ended December 31, 2017 Marketwired
Mar-27-18 08:30AM  Moleculin Enters Agreement with Seidman Cancer Center to Conduct Leukemia Clinical Trials Marketwired
Mar-20-18 08:30AM  Moleculin Announces Grant-Funded Collaboration to Expand Understanding of New Discovery Marketwired
Mar-06-18 08:30AM  Moleculin to Present at the 30th Annual ROTH Conference Tuesday, March 13, 2018 Marketwired
Mar-02-18 10:03AM  The Market In 5 Minutes: Trump, Tariffs, Trade Wars And More Benzinga +5.82%
Mar-01-18 05:06PM  ICYMI: Snapchat, Molecular Biotech's CEO Speaks, SEC Examines Crypto ICOs Benzinga -5.03%
Feb-28-18 10:05AM  Reminder: Moleculin Announces Conference Call to Discuss Recent Discovery of New Molecule and Business Update on Wednesday, February 28, 2018 Marketwired
Feb-22-18 08:30AM  Moleculin Announces Conference Call to Discuss Recent Discovery of New Molecule and Business Update on Wednesday, February 28, 2018 Marketwired
Feb-16-18 02:31PM  Heres Why Moleculin Biotech Inc (MBRX) Is Down Big Today SmarterAnalyst -26.07%
01:20PM  Moleculin Biotech's Volatility, Explained Benzinga
08:28AM  Moleculin Announces Pricing of $9 Million Registered Direct Offering Marketwired
Feb-15-18 10:57AM  Moleculin Biotech's stock rockets after 'major breakthrough' in cancer treatment MarketWatch +53.85%
08:30AM  Moleculin Announces Breakthrough Discovery of a New Molecule for Cancer Treatment Marketwired
Feb-13-18 08:30AM  Moleculin Announces Collaboration with Emory University to Develop Novel Treatment of Pediatric Brain Cancer Marketwired
Feb-07-18 08:30AM  Moleculin Announces Activity with Pancreatic Cancer Drug Marketwired
Jan-17-18 08:30AM  Leading Leukemia Experts Join Moleculin's Science Advisory Board Marketwired
Jan-10-18 08:30AM  Moleculin Expands Leukemia Development Portfolio with Immuno-Stimulating STAT3 Inhibitor Marketwired
Dec-21-17 08:30AM  Moleculin Announces Polish Approval for Leukemia Clinical Trial Marketwired
Dec-06-17 10:01AM  Moleculin's WP1066 Drug receives $2 million Private Grant Marketwired -9.13%
08:10AM  Todays Research Reports on Trending Tickers: ACADIA Pharmaceuticals and Moleculin Biotech ACCESSWIRE
Dec-05-17 07:00AM  Moleculin's WP1066 Drug gets FDA Brain Tumor IND Clearance Marketwired +14.29%
Nov-28-17 03:06PM  Why Moleculin Biotech Incs (MBRX) Ownership Structure Is Important Simply Wall St.
Nov-21-17 07:30AM  Moleculin to Present at the 10th Annual LD Micro Main Event on December 5, 2017 at 11:30 a.m. PT Marketwired
Nov-14-17 07:00AM  Moleculin Biotech, Inc. Reports Financial Results for the Third Quarter Ended September 30, 2017 Marketwired
Nov-08-17 07:30AM  Moleculin Appoints Dr. Sandra Silberman as Chief Medical Officer -- New Products Marketwired
Nov-01-17 07:30AM  Moleculin Announces MD Anderson has Filed an IND with the FDA on its Drug WP1066 for the Treatment of Brain Tumors Marketwired
Oct-24-17 07:30AM  Moleculin Requests Authorization from the Polish Government to Advance Annamycin Marketwired -8.96%
Oct-18-17 07:30AM  Moleculin Announces 14 Qualified Clinical Sites Requesting Participation in Annamycin Trial Marketwired +7.94%
Oct-11-17 07:30AM  Moleculin Announces Strategic Collaboration to Develop Immune Stimulation Drug Marketwired
Oct-05-17 07:10AM  Corporate News Blog - Moleculin Biotech Signs Agreement with the First Hospital to Conduct Clinical Trials for Annamycin ACCESSWIRE
Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of oncology drug candidates. Its lead drug candidate is Annamycin that is in Phase I/II clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) in the United States and Poland. The company's flagship immune/transcription modulator is WP1066, a STAT3 inhibitor, which is in Phase I clinical trial for the treatment of brain tumor, as well as to treat pancreatic cancer, AML, and glioblastoma. It also develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma in Poland; and WP1732, an analog of WP1066 for the treatment of AML, pancreatic, and other cancers. The company's lead metabolism/glycosylation inhibitor compound is WP1122, a prodrug of 2-deoxyglucose to treat brain tumors and pancreatic cancer. In addition, it develops WP1234 for the treatment of pancreatic cancer. Further, the company engages in the preclinical development of other drug candidates, including other immune/transcription modulators and metabolism/glycosylation inhibitors. It has an agreement with the University of Iowa Pharmaceuticals for the development of a formulation for WP1732; collaboration with Dermin Sp. zoo for the development of WP1220; and collaboration with M.D. Anderson Cancer Center for the development of WP1732 and WP1066. Moleculin Biotech, Inc. was founded in 2015 and is headquartered in Houston, Texas.